目的:探索血清乳酸脱氢酶(LDH)水平对急性髓细胞白血病患者临床预后的预测价值。方法:回顾性收集我院135例核型正常的急性髓细胞白血病(CN-AML)患者治疗前的血清LDH数值和相关临床信息,采用Survival ROC软件包确立LDH水平预测总生存期的最佳界定值,高于界定值定义为高水平组,低于界定值为低水平组。结合年龄、白细胞计数、FLT3-ITD和NPM1突变等预后信息,采用Cox回归模型分析不同水平LDH对总生存期及无事件生存期的预测价值。结果:血清LDH预测CN-AML患者总生存期的最佳界定值为294U/L,灵敏度92%,特异度84%。不同水平LDH可独立预测CN-AML的临床预后,高水平LDH的CNAML患者预后差。结论:高水平的LDH与CN-AML患者不良预后密切相关。 Objective: To explore the predictive value of serum lactate dehydrogenase (LDH) level in the prognosis of patients with acute myeloid leukemia. Methods: The serum LDH levels and related clinical information of 135 patients with normal myelocytic leukemia (CN-AML) before treatment were retrospectively collected. Survival ROC software package was used to establish the best definition of LDH predicting the overall survival Value, above the defined value is defined as the high level group, below the defined value for the low level group. Combined with age, WBC count, FLT3-ITD and NPM1 mutation prognostic information, Cox regression model was used to analyze the predictive value of different levels of LDH for overall survival and event-free survival. Results: The optimal serum concentration of LDH for predicting the overall survival of patients with CN-AML was 294U / L with a sensitivity of 92% and a specificity of 84%. Different levels of LDH independently predict the clinical outcome of CN-AML, and patients with high-level LDH have a poor prognosis. Conclusions: High levels of LDH are associated with poor prognosis in patients with CN-AML.